{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:34:49Z","timestamp":1793414089761,"version":"4.5.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2019\/00164-0"],"award-info":[{"award-number":["2019\/00164-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universidade Estadual Paulista J\u00falio De Mesquita Filho","id":[{"id":"https:\/\/ror.org\/00987cb86","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-oral drug delivery routes, including cutaneous, transdermal, pulmonary, ophthalmic, parenteral, vaginal, and rectal administration, are essential for both local and systemic therapies but impose route-specific constraints on drug dissolution, retention, permeation, clearance, and exposure. Amorphous solid dispersions (ASDs),extensively investigated for oral delivery, may improve the performance of poorly water-soluble drugs by stabilizing high-energy amorphous states, increasing apparent solubility, and promoting transient supersaturation. However, their translation into non-oral dosage forms remains fragmented and largely preclinical.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This review critically examines the potential, limitations, and translational challenges of ASDs for non-oral drug delivery, with emphasis on the physicochemical, biopharmaceutical, pharmaceutical, and route-dependent determinants governing their performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Scope<\/jats:title>\n                    <jats:p>Key aspects discussed include drug\u2013polymer interactions, molecular mobility, phase behavior, water uptake, crystallization, interactions with secondary pharmaceutical bases, and route-specific pharmacokinetic\/pharmacodynamic relationships. Current evidence is examined across dermal, transdermal, pulmonary, ophthalmic, vaginal, rectal, and parenteral delivery systems. Parenteral administration is considered a special case encompassing sterile suspensions, reconstitutable systems, microneedles, implants, and depot-forming formulations. Recent technological advances, patent and industrial landscapes, and the potential extension of ASD principles to peptides, proteins, biologics, and other complex molecular entities are also addressed. ASDs are further positioned in relation to alternative and complementary solubility-enhancing technologies, including nanoparticles, nanocrystals, cocrystals, cyclodextrins, micelles, lipid-based systems, emulsions, solvents, and cosolvents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ASDs off er a promising but still underdeveloped strategy for improving non-oral delivery of poorly soluble drugs. Their successful translation will depend not only on achieving and maintaining favorable amorphousstates and supersaturation, but also on converting these physicochemical advantages into route-specific drug exposure, therapeutic benefit, formulation stability, manufacturability, and clinically meaningful outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11095-026-04200-6","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:06:51Z","timestamp":1789675611000},"page":"3057-3081","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Amorphous Solid Dispersions in Non-Oral Drug Delivery: A Critical Review Bridging Mechanistic Advantages and Gaps in Translational Evidence"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2370-0662","authenticated-orcid":false,"given":"Bruno Vincenzo Fiod","family":"Riccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline Franciane","family":"Le\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz","family":"Klosowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Isadora","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Miziara Barboza","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maur\u00edcio Palmeira Chaves","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscileila Colerato","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlus","family":"Chorilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"4200_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114293","volume":"186","author":"Y Mohammed","year":"2022","unstructured":"Mohammed Y, Holmes A, Kwok PCL, Kumeria T, Namjoshi S, Imran M, et al. Advances and future perspectives in epithelial drug delivery. Adv Drug Deliv Rev. 2022;186:114293. https:\/\/doi.org\/10.1016\/j.addr.2022.114293.","journal-title":"Adv Drug Deliv Rev"},{"key":"4200_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1333986","volume":"14","author":"L Zhao","year":"2024","unstructured":"Zhao L, Chen J, Bai B, Song G, Zhang J, Yu H, et al. Topical drug delivery strategies for enhancing drug effectiveness by skin barriers, drug delivery systems, and individualized dosing. Front Pharmacol. 2024;14:1333986. https:\/\/doi.org\/10.3389\/fphar.2023.1333986.","journal-title":"Front Pharmacol"},{"issue":"5","key":"4200_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17050599","volume":"17","author":"S Gade","year":"2025","unstructured":"Gade S, So Y, Mishra D, Baviskar SM, Assiri AA, Glover K, et al. Ocular drug delivery: emerging approaches and advances. Pharmaceutics. 2025;17(5):599. https:\/\/doi.org\/10.3390\/pharmaceutics17050599.","journal-title":"Pharmaceutics"},{"issue":"4","key":"4200_CR4","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1021\/acs.molpharmaceut.4c01534","volume":"22","author":"B Forbes","year":"2025","unstructured":"Forbes B, B\u00e4ckman P, Cabal A, Clark A, Ehrhardt C, Hastedt JE, et al. iBCS: 4. Application of the Inhalation Biopharmaceutics Classification System to the development of orally inhaled drug products. Mol Pharm. 2025;22(4):1740\u201351. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c01534.","journal-title":"Mol Pharm"},{"issue":"4","key":"4200_CR5","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.apsb.2025.12.003","volume":"16","author":"A Chen","year":"2026","unstructured":"Chen A, Peng YY, Chen ZZ, Lu Y, Guo MS, Cai T. Crystal engineering for poorly water-soluble drugs: From design to applications. Acta Pharm Sin B. 2026;16(4):1848\u201382. https:\/\/doi.org\/10.1016\/j.apsb.2025.12.003.","journal-title":"Acta Pharm Sin B"},{"key":"4200_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2024.114513","volume":"204","author":"I Nyamba","year":"2024","unstructured":"Nyamba I, Sombi\u00e9 CB, Yabr\u00e9 M, Zim\u00e9-Diawara H, Yam\u00e9ogo J, Ou\u00e9draogo S, et al. Pharmaceutical approaches for enhancing solubility and oral bioavailability of poorly soluble drugs. Eur J Pharm Biopharm. 2024;204:114513. https:\/\/doi.org\/10.1016\/j.ejpb.2024.114513.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"4200_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/10717544.2019.1704940","volume":"27","author":"A Schittny","year":"2020","unstructured":"Schittny A, Huwyler J, Puchkov M. Mechanisms of increased bioavailability through amorphous solid dispersions: a review. Drug Deliv. 2020;27(1):110\u201327. https:\/\/doi.org\/10.1080\/10717544.2019.1704940.","journal-title":"Drug Deliv"},{"issue":"3","key":"4200_CR8","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1021\/acs.molpharmaceut.3c01106","volume":"21","author":"P Bapat","year":"2024","unstructured":"Bapat P, Paul S, Tseng YC, Taylor LS. Interplay of drug-polymer interactions and release performance for HPMCAS-based amorphous solid dispersions. Mol Pharm. 2024;21(3):1466\u201378. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c01106.","journal-title":"Mol Pharm"},{"issue":"11","key":"4200_CR9","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1021\/acs.molpharmaceut.2c00479","volume":"19","author":"A Pugliese","year":"2022","unstructured":"Pugliese A, Tobyn M, Hawarden LE, Abraham A, Blanc F. New development in understanding drug-polymer interactions in pharmaceutical amorphous solid dispersions from solid-state nuclear magnetic resonance. Mol Pharm. 2022;19(11):3685\u201399. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00479.","journal-title":"Mol Pharm"},{"issue":"9","key":"4200_CR10","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1021\/acs.molpharmaceut.3c00184","volume":"20","author":"A Kambayashi","year":"2023","unstructured":"Kambayashi A. In silico modeling approaches coupled with in vitro characterization in predicting in vivo performance of drug delivery system formulations. Mol Pharm. 2023;20(9):4344\u201353. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00184.","journal-title":"Mol Pharm"},{"key":"4200_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2024.114274","volume":"198","author":"X Zhuo","year":"2024","unstructured":"Zhuo X, Ochner J, Leng D, Foder\u00e0 V, L\u00f6bmann K. Exploring the effect of protein secondary structure on the solid state and physical stability of protein-based amorphous solid dispersions. Eur J Pharm Biopharm. 2024;198:114274. https:\/\/doi.org\/10.1016\/j.ejpb.2024.114274.","journal-title":"Eur J Pharm Biopharm"},{"key":"4200_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.122524","volume":"631","author":"Y Kong","year":"2023","unstructured":"Kong Y, Wang W, Wang C, Li L, Peng D, Tian B. Supersaturation and phase behavior during dissolution of amorphous solid dispersions. Int J Pharm. 2023;631:122524. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122524.","journal-title":"Int J Pharm"},{"issue":"1","key":"4200_CR13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.xphs.2022.10.021","volume":"112","author":"R Yang","year":"2023","unstructured":"Yang R, Zhang GGZ, Zemlyanov DY, Purohit HS, Taylor LS. Release Mechanisms of Amorphous Solid Dispersions: Role of Drug-Polymer Phase Separation and Morphology. J Pharm Sci. 2023;112(1):304\u201317. https:\/\/doi.org\/10.1016\/j.xphs.2022.10.021.","journal-title":"J Pharm Sci"},{"issue":"1","key":"4200_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1021\/acs.molpharmaceut.1c00578","volume":"19","author":"PD Nunes","year":"2022","unstructured":"Nunes PD, Pinto JF, Henriques J, Paiva AM, Vodak DT. Insights into the Release Mechanisms of ITZ:HPMCAS Amorphous Solid Dispersions: The Role of Drug-Rich Colloids. Mol Pharm. 2022;19(1):51\u201366. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00578.","journal-title":"Mol Pharm"},{"issue":"5","key":"4200_CR15","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1021\/acs.molpharmaceut.1c00055","volume":"18","author":"R Yang","year":"2021","unstructured":"Yang R, Mann AKP, Duong TV, Ormes JD, Okoh GA, Hermans A, et al. Drug release and nanodroplet formation from amorphous solid dispersions: insight into the roles of drug physicochemical properties and polymer selection. Mol Pharm. 2021;18(5):2066\u201381. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00055.","journal-title":"Mol Pharm"},{"issue":"9","key":"4200_CR16","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1021\/acs.molpharmaceut.4c00342","volume":"21","author":"I Antolovi\u0107","year":"2024","unstructured":"Antolovi\u0107 I, Vrabec J, Klajmon M. COSMOPharm: drug-polymer compatibility of pharmaceutical amorphous solid dispersions from COSMO-SAC. Mol Pharm. 2024;21(9):4395\u2013415. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00342.","journal-title":"Mol Pharm"},{"issue":"4","key":"4200_CR17","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1021\/acs.molpharmaceut.9b01272","volume":"17","author":"S Saboo","year":"2020","unstructured":"Saboo S, Kestur US, Taylor LS. Congruent Release of Drug and Polymer from Amorphous Solid Dispersions: Insights into the Role of Drug-Polymer Hydrogen Bonding, Surface Crystallization, and Glass Transition. Mol Pharm. 2020;17(4):1261\u201375. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b01272.","journal-title":"Mol Pharm"},{"issue":"7","key":"4200_CR18","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1021\/acs.molpharmaceut.2c00188","volume":"19","author":"F Wolbert","year":"2022","unstructured":"Wolbert F, Nikoleit K, Steinbrink M, Luebbert C, Sadowski G. The shelf life of ASDs: 1. Measuring the crystallization kinetics at humid conditions. Mol Pharm. 2022;19(7):2483\u201394. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00188.","journal-title":"Mol Pharm"},{"issue":"2","key":"4200_CR19","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1021\/acs.molpharmaceut.3c01056","volume":"21","author":"B Gr\u00f6nniger","year":"2024","unstructured":"Gr\u00f6nniger B, Nikoleit K, Wolbert F, Sadowski G. Simultaneous Water Sorption and Crystallization in ASDs 1: Stability Studies Lasting for Two Years. Mol Pharm. 2024;21(2):957\u201369. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c01056.","journal-title":"Mol Pharm"},{"issue":"11","key":"4200_CR20","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.1021\/acs.molpharmaceut.4c00935","volume":"21","author":"NS Krishna Kumar","year":"2024","unstructured":"Krishna Kumar NS, Lalge R, Suryanarayanan R. Time and temperature dependence of drug crystallization-the role of molecular mobility. Mol Pharm. 2024;21(11):5880\u201391. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00935.","journal-title":"Mol Pharm"},{"issue":"8","key":"4200_CR21","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1007\/s13346-024-01614-w","volume":"14","author":"RH Guy","year":"2024","unstructured":"Guy RH. Drug delivery to and through the skin. Drug Deliv Transl Res. 2024;14(8):2032\u201340. https:\/\/doi.org\/10.1007\/s13346-024-01614-w.","journal-title":"Drug Deliv Transl Res"},{"issue":"2","key":"4200_CR22","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-023-02516-9","volume":"24","author":"S Ahmed","year":"2023","unstructured":"Ahmed S, Amin MM, Sayed S. Ocular drug delivery: a comprehensive review. AAPS PharmSciTech. 2023;24(2):66. https:\/\/doi.org\/10.1208\/s12249-023-02516-9.","journal-title":"AAPS PharmSciTech"},{"issue":"11","key":"4200_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14112487","volume":"14","author":"X Jin","year":"2022","unstructured":"Jin X, Imran M, Mohammed Y. Topical semisolid products\u2014understanding the impact of metamorphosis on skin penetration and physicochemical properties. Pharmaceutics. 2022;14(11):2487. https:\/\/doi.org\/10.3390\/pharmaceutics14112487.","journal-title":"Pharmaceutics"},{"issue":"9","key":"4200_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12090859","volume":"12","author":"B Vigani","year":"2020","unstructured":"Vigani B, Rossi S, Sandri G, Bonferoni MC, Caramella CM, Ferrari F. Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes. Pharmaceutics. 2020;12(9):859. https:\/\/doi.org\/10.3390\/pharmaceutics12090859.","journal-title":"Pharmaceutics"},{"issue":"1","key":"4200_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/polym1301002","volume":"13","author":"M Pandey","year":"2021","unstructured":"Pandey M, Choudhury H, Abdul-Aziz A, Bhattamisra SK, Gorain B, Carine T, et al. Promising Drug Delivery Approaches to Treat Microbial Infections in the Vagina: A Recent Update. Polymers. 2021;13(1):26. https:\/\/doi.org\/10.3390\/polym1301002.","journal-title":"Polymers"},{"issue":"10","key":"4200_CR26","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.3390\/pharmaceutics14102210","volume":"14","author":"R Rathi","year":"2022","unstructured":"Rathi R, Chauhan I, Kesharwani P, Gorain B. Advancements in Rectal Drug Delivery Systems. Pharmaceutics. 2022;14(10):2210. https:\/\/doi.org\/10.3390\/pharmaceutics14102210.","journal-title":"Pharmaceutics"},{"key":"4200_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105807","volume":"97","author":"S Mondal","year":"2024","unstructured":"Mondal S, Kollipara S, Chougule M, Bhatia A, et al. Biopredictive Dissolutions for Conventional IR, MR and Non-Oral Formulations \u2013 Current Status and Future Opportunities. J Drug Deliv Sci Technol. 2024;97:105807. https:\/\/doi.org\/10.1016\/j.jddst.2024.105807.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"6","key":"4200_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061707","volume":"15","author":"X Jin","year":"2023","unstructured":"Jin X, Alavi SE, Shafiee A, Leite-Silva VR, Khosrotehrani K, Mohammed Y. Metamorphosis of topical semisolid products\u2014understanding the role of rheological properties in drug permeation under the \u201cin use\u201d condition. Pharmaceutics. 2023;15(6):1707. https:\/\/doi.org\/10.3390\/pharmaceutics15061707.","journal-title":"Pharmaceutics"},{"issue":"7","key":"4200_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12070684","volume":"12","author":"C Gorzelanny","year":"2020","unstructured":"Gorzelanny C, Mess C, Schneider SW, Huck V, Brandner JM. Skin barriers in dermal drug delivery: which barriers have to be overcome and how can we measure them? Pharmaceutics. 2020;12(7):684. https:\/\/doi.org\/10.3390\/pharmaceutics12070684.","journal-title":"Pharmaceutics"},{"key":"4200_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.106117","volume":"100","author":"Z Hou","year":"2024","unstructured":"Hou Z, Zhao X, Ding J. First promising non-stimulant (guanfacine) transdermal patch for long-acting treatment of ADHD by solid dispersion technique. J Drug Deliv Sci Technol. 2024;100:106117. https:\/\/doi.org\/10.1016\/j.jddst.2024.106117.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"6","key":"4200_CR31","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3390\/pharmaceutics14061149","volume":"14","author":"BVF Riccio","year":"2022","unstructured":"Riccio BVF, Nascimento ALCS, Meneguin AB, Rodero CF, Santos KP, S\u00e1bio RM, et al. Solid Dispersions Incorporated into PVP Films for the Controlled Release of Trans-Resveratrol: Development, Physicochemical and In Vitro Characterizations and In Vivo Cutaneous Anti-Inflammatory Evaluation. Pharmaceutics. 2022;14(6):1149. https:\/\/doi.org\/10.3390\/pharmaceutics14061149.","journal-title":"Pharmaceutics"},{"key":"4200_CR32","doi-asserted-by":"publisher","unstructured":"AboulFotouh K, Zhang Y, Maniruzzaman M, Williams RO III, Cui Z. Amorphous solid dispersion dry powder for pulmonary drug delivery: advantages and challenges. Int J Pharm. 2020;587:119711. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119711.","DOI":"10.1016\/j.ijpharm.2020.119711"},{"key":"4200_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104553","volume":"84","author":"HI Shahin","year":"2023","unstructured":"Shahin HI, Chablani L. A comprehensive overview of dry powder inhalers for pulmonary drug delivery: challenges, advances, optimization techniques, and applications. J Drug Deliv Sci Technol. 2023;84:104553. https:\/\/doi.org\/10.1016\/j.jddst.2023.104553.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"4200_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jconrel.2009.04.014","volume":"138","author":"S Onoue","year":"2009","unstructured":"Onoue S, Sato H, Ogawa K, Kojo Y, Aoki Y, Kawabata Y, et al. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy. J Control Release. 2009;138(1):16\u201323. https:\/\/doi.org\/10.1016\/j.jconrel.2009.04.014.","journal-title":"J Control Release"},{"issue":"12","key":"4200_CR35","doi-asserted-by":"publisher","first-page":"6246","DOI":"10.1021\/acs.molpharmaceut.3c00647","volume":"20","author":"MAS Mahfud","year":"2023","unstructured":"Mahfud MAS, Syahirah NA, Akram M, Mahfufah U, Saputra MD, Elim D, et al. Solid dispersion incorporated into dissolving microneedles for improved antifungal activity of amphotericin B: in vivo study in a fungal keratitis model. Mol Pharm. 2023;20(12):6246\u201361. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00647.","journal-title":"Mol Pharm"},{"issue":"15","key":"4200_CR36","doi-asserted-by":"publisher","first-page":"18128","DOI":"10.1021\/acsami.1c03422","volume":"13","author":"AD Permana","year":"2021","unstructured":"Permana AD, Utomo E, Pratama MR, Amir MN, Anjani QK, Mardikasari SA, et al. Bioadhesive-thermosensitive in situ vaginal gel of the gel flake-solid dispersion of itraconazole for enhanced antifungal activity in the treatment of vaginal candidiasis. ACS Appl Mater Interfaces. 2021;13(15):18128\u201341. https:\/\/doi.org\/10.1021\/acsami.1c03422.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"4200_CR37","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1208\/s12249-017-0839-5","volume":"19","author":"Y Liu","year":"2018","unstructured":"Liu Y, Wang X, Liu Y, Di X. Thermosensitive In Situ Gel Based on Solid Dispersion for Rectal Delivery of Ibuprofen. AAPS PharmSciTech. 2018;19(1):338\u201347. https:\/\/doi.org\/10.1208\/s12249-017-0839-5.","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"4200_CR38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.14227\/DT310424P162","volume":"31","author":"M Sakagami","year":"2024","unstructured":"Sakagami M, Fotaki N. Testing the in vitro product performance of inhalation and nasal drug products: views of the USP Expert Panel. Dissolution Technol. 2024;31(4):162\u201372. https:\/\/doi.org\/10.14227\/DT310424P162.","journal-title":"Dissolution Technol"},{"issue":"7","key":"4200_CR39","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s11095-024-03736-9","volume":"41","author":"YH Mohammed","year":"2024","unstructured":"Mohammed YH, Namjoshi SN, Jung N, Windbergs M, Benson HAE, Grice JE, et al. Topical semisolid drug product critical quality attributes with relevance to cutaneous bioavailability and pharmacokinetics: part I-bioequivalence of acyclovir topical creams. Pharm Res. 2024;41(7):1507\u201320. https:\/\/doi.org\/10.1007\/s11095-024-03736-9.","journal-title":"Pharm Res"},{"issue":"4","key":"4200_CR40","doi-asserted-by":"publisher","first-page":"204","DOI":"10.14227\/DT290422P204","volume":"29","author":"DM D\u2019Arcy","year":"2022","unstructured":"D\u2019Arcy DM, Wacker MG, Klein S, Shah V, Burke MD, Hunter G, et al. In-vitro product performance of parenteral drug products: view of the USP Expert Panel. Dissolution Technol. 2022;29(4):204\u201318. https:\/\/doi.org\/10.14227\/DT290422P204.","journal-title":"Dissolution Technol"},{"key":"4200_CR41","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2016.01.002","volume":"100","author":"L Chen","year":"2016","unstructured":"Chen L, Okuda T, Lu XY, Chan HK. Amorphous powders for inhalation drug delivery. Adv Drug Deliv Rev. 2016;100:102\u201315. https:\/\/doi.org\/10.1016\/j.addr.2016.01.002.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"4200_CR42","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s11095-022-03391-y","volume":"40","author":"A Bauer","year":"2023","unstructured":"Bauer A, Berben P, Chakravarthi SS, Chattorraj S, Garg A, Gourdon B, et al. Current state and opportunities with long-acting injectables: industry perspectives from the Innovation and Quality Consortium \u201cLong-Acting Injectables\u201d Working Group. Pharm Res. 2023;40(7):1601\u201331. https:\/\/doi.org\/10.1007\/s11095-022-03391-y.","journal-title":"Pharm Res"},{"issue":"3","key":"4200_CR43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1208\/s12248-023-00811-8","volume":"25","author":"R Holm","year":"2023","unstructured":"Holm R, Lee RW, Glassco J, DiFranco N, Bao Q, Burgess DJ, et al. Long-Acting Injectable Aqueous Suspensions\u2014Summary From an AAPS Workshop. AAPS J. 2023;25(3):49. https:\/\/doi.org\/10.1208\/s12248-023-00811-8.","journal-title":"AAPS J"},{"issue":"3","key":"4200_CR44","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1124\/jpet.119.257113","volume":"370","author":"PM Glassman","year":"2019","unstructured":"Glassman PM, Muzykantov VR. Pharmacokinetic and pharmacodynamic properties of drug delivery systems. J Pharmacol Exp Ther. 2019;370(3):570\u201380. https:\/\/doi.org\/10.1124\/jpet.119.257113.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"4200_CR45","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","volume":"12","author":"R Gaudana","year":"2010","unstructured":"Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular Drug Delivery. AAPS J. 2010;12(3):348\u201360. https:\/\/doi.org\/10.1208\/s12248-010-9183-3.","journal-title":"AAPS J"},{"issue":"22","key":"4200_CR46","doi-asserted-by":"publisher","first-page":"19145","DOI":"10.1021\/acsomega.2c08016","volume":"8","author":"N Raina","year":"2023","unstructured":"Raina N, Rani R, Thakur VK, Gupta M. New Insights in Topical Drug Delivery for Skin Disorders: From a Nanotechnological Perspective. ACS Omega. 2023;8(22):19145\u201367. https:\/\/doi.org\/10.1021\/acsomega.2c08016.","journal-title":"ACS Omega"},{"key":"4200_CR47","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13346-020-00864-8","volume":"11","author":"MAM Tabosa","year":"2021","unstructured":"Tabosa MAM, Hoppel M, Bunge AL, Guy RH, Delgado-Charro MB. Predicting topical drug clearance from the skin. Drug Deliv Transl Res. 2021;11:729\u201340. https:\/\/doi.org\/10.1007\/s13346-020-00864-8.","journal-title":"Drug Deliv Transl Res"},{"issue":"9","key":"4200_CR48","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1021\/acs.molpharmaceut.4c00665","volume":"21","author":"S Alidori","year":"2024","unstructured":"Alidori S, Subramanian R, Holm R. Patient-centric long-acting injectable and implantable platforms\u2014an industrial perspective. Mol Pharm. 2024;21(9):4238\u201358. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00665.","journal-title":"Mol Pharm"},{"issue":"8","key":"4200_CR49","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/17425247.2022.2105318","volume":"19","author":"A Gonella","year":"2022","unstructured":"Gonella A, Grizot S, Liu F, L\u00f3pez Noriega A, Richard J. Long-acting injectable formulation technologies: challenges and opportunities for the delivery of fragile molecules. Expert Opin Drug Deliv. 2022;19(8):927\u201344. https:\/\/doi.org\/10.1080\/17425247.2022.2105318.","journal-title":"Expert Opin Drug Deliv"},{"key":"4200_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.123550","volume":"648","author":"S Nandi","year":"2023","unstructured":"Nandi S, Padrela L, Tajber L, Collas A. Development of long-acting injectable suspensions by continuous antisolvent crystallization: an integrated bottom-up process. Int J Pharm. 2023;648:123550. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.123550.","journal-title":"Int J Pharm"},{"issue":"2","key":"4200_CR51","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.jconrel.2012.04.016","volume":"161","author":"S Kempe","year":"2012","unstructured":"Kempe S, M\u00e4der K. In situ forming implants\u2014an attractive formulation principle for parenteral depot formulations. J Control Release. 2012;161(2):668\u201379. https:\/\/doi.org\/10.1016\/j.jconrel.2012.04.016.","journal-title":"J Control Release"},{"issue":"3","key":"4200_CR52","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-021-01965-4","volume":"22","author":"J Kozak","year":"2021","unstructured":"Kozak J, Rabiskova M, Lamprecht A. Muscle tissue as a surrogate for in vitro drug release testing of parenteral depot microspheres. AAPS PharmSciTech. 2021;22(3):119. https:\/\/doi.org\/10.1208\/s12249-021-01965-4.","journal-title":"AAPS PharmSciTech"},{"key":"4200_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113793","volume":"383","author":"J Liu","year":"2025","unstructured":"Liu J, Xu Z, Wu D, Leithead A, Johnson AR, Zhang Y, et al. Particle size matters: the impact of particle size on properties and performance of long-acting injectable crystalline aqueous suspensions. J Control Release. 2025;383:113793. https:\/\/doi.org\/10.1016\/j.jconrel.2025.113793.","journal-title":"J Control Release"},{"issue":"9","key":"4200_CR54","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1016\/j.xphs.2015.10.008","volume":"105","author":"S Baghel","year":"2016","unstructured":"Baghel S, Cathcart H, O\u2019Reilly NJ. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs. J Pharm Sci. 2016;105(9):2527\u201344. https:\/\/doi.org\/10.1016\/j.xphs.2015.10.008.","journal-title":"J Pharm Sci"},{"issue":"5","key":"4200_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28052212","volume":"28","author":"Y Gan","year":"2023","unstructured":"Gan Y, Baak JPA, Chen T, Ye H, Liao W, Lv H, et al. Supersaturation and precipitation applicated in drug delivery systems: development strategies and evaluation approaches. Molecules. 2023;28(5):2212. https:\/\/doi.org\/10.3390\/molecules28052212.","journal-title":"Molecules"},{"issue":"2","key":"4200_CR56","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s13346-022-01223-5","volume":"13","author":"K Panchal","year":"2023","unstructured":"Panchal K, Katke S, Dash SK, Gaur A, Shinde A, Saha N, et al. An expanding horizon of complex injectable products: development and regulatory considerations. Drug Deliv Transl Res. 2023;13(2):433\u201372. https:\/\/doi.org\/10.1007\/s13346-022-01223-5.","journal-title":"Drug Deliv Transl Res"},{"issue":"3","key":"4200_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12030724","volume":"12","author":"C Kato","year":"2023","unstructured":"Kato C, Itaya-Takahashi M, Miyazawa T, Ito J, Parida IS, Yamada H, et al. Effects of particle size of curcumin solid dispersions on bioavailability and anti-inflammatory activities. Antioxidants. 2023;12(3):724. https:\/\/doi.org\/10.3390\/antiox12030724.","journal-title":"Antioxidants"},{"key":"4200_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121474","volume":"615","author":"T Ren","year":"2022","unstructured":"Ren T, Chen J, Qi P, Xiao P, Wang P. Goserelin\/PLGA Solid Dispersion Used to Prepare Long-acting Microspheres with Reduced Initial Release and Reduced Fluctuation of Drug Serum Concentration In Vivo. Int J Pharm. 2022;615:121474. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121474.","journal-title":"Int J Pharm"},{"issue":"11","key":"4200_CR59","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.1021\/acsbiomaterials.0c01228","volume":"6","author":"J Yoo","year":"2020","unstructured":"Yoo J, Won YY. Phenomenology of the initial burst release of drugs from PLGA microparticles. ACS Biomater Sci Eng. 2020;6(11):6053\u201362. https:\/\/doi.org\/10.1021\/acsbiomaterials.0c01228.","journal-title":"ACS Biomater Sci Eng"},{"issue":"5","key":"4200_CR60","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41578-021-00405-w","volume":"7","author":"W Li","year":"2022","unstructured":"Li W, Tang J, Lee D, Tice TR, Schwendeman SP, Prausnitz MR. Clinical translation of long-acting drug delivery formulations. Nat Rev Mater. 2022;7(5):406\u201320. https:\/\/doi.org\/10.1038\/s41578-021-00405-w.","journal-title":"Nat Rev Mater"},{"key":"4200_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119475","volume":"586","author":"K Nieto","year":"2020","unstructured":"Nieto K, Mallery SR, Schwendeman SP. Microencapsulation of Amorphous Solid Dispersions of Fenretinide Enhances Drug Solubility and Release from PLGA in Vitro and In Vivo. Int J Pharm. 2020;586:119475. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119475.","journal-title":"Int J Pharm"},{"issue":"16","key":"4200_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/polym13162815","volume":"13","author":"FK Aldawood","year":"2021","unstructured":"Aldawood FK, Andar A, Desai S. A comprehensive review of microneedles: types, materials, processes, characterizations and applications. Polymers (Basel). 2021;13(16):2815. https:\/\/doi.org\/10.3390\/polym13162815.","journal-title":"Polymers (Basel)"},{"issue":"5","key":"4200_CR63","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1517\/17425247.2012.676038","volume":"9","author":"S Al-Zahrani","year":"2012","unstructured":"Al-Zahrani S, Zaric M, McCrudden C, Scott C, Kissenpfennig A, Donnelly RF. Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy. Expert Opin Drug Deliv. 2012;9(5):541\u201350. https:\/\/doi.org\/10.1517\/17425247.2012.676038.","journal-title":"Expert Opin Drug Deliv"},{"key":"4200_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s40824-023-00390-x","volume":"27","author":"J Shi","year":"2023","unstructured":"Shi J, Ma Q, Su W, Liu C, Zhang H, Liu Y, et al. Effervescent cannabidiol solid dispersion-doped dissolving microneedles for boosted melanoma therapy via the \u201cTRPV1-NFATc1-ATF3\u201d pathway and tumor microenvironment engineering. Biomater Res. 2023;27:48. https:\/\/doi.org\/10.1186\/s40824-023-00390-x.","journal-title":"Biomater Res"},{"key":"4200_CR65","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.addr.2015.02.001","volume":"92","author":"CM Caramella","year":"2015","unstructured":"Caramella CM, Rossi S, Ferrari F, Bonferoni MC, Sandri G. Mucoadhesive and thermogelling systems for vaginal drug delivery. Adv Drug Deliv Rev. 2015;92:39\u201352. https:\/\/doi.org\/10.1016\/j.addr.2015.02.001.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"4200_CR66","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.3390\/ijms22115500","volume":"22","author":"M Bialik","year":"2021","unstructured":"Bialik M, Kuras M, Sobczak M, Oledzka E. Achievements in Thermosensitive Gelling Systems for Rectal Administration. Int J Mol Sci. 2021;22(11):5500. https:\/\/doi.org\/10.3390\/ijms22115500.","journal-title":"Int J Mol Sci"},{"key":"4200_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114167","volume":"387","author":"M Balash","year":"2025","unstructured":"Balash M, Boucetta H, He W. Factors affecting drug delivery system translation: A focus on advanced technologies, biological barriers, and regulatory challenges. J Control Release. 2025;387:114167. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114167.","journal-title":"J Control Release"},{"key":"4200_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119560","volume":"586","author":"P Pandi","year":"2020","unstructured":"Pandi P, Bulusu R, Kommineni N, Khan W, Singh M. Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products. Int J Pharm. 2020;586:119560. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119560.","journal-title":"Int J Pharm"},{"issue":"10","key":"4200_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14102203","volume":"14","author":"S Tambe","year":"2022","unstructured":"Tambe S, Jain D, Meruva SK, Rongala G, Juluri A, Nihalani G, et al. Recent advances in amorphous solid dispersions: preformulation, formulation strategies, technological advancements and characterization. Pharmaceutics. 2022;14(10):2203. https:\/\/doi.org\/10.3390\/pharmaceutics14102203.","journal-title":"Pharmaceutics"},{"issue":"1","key":"4200_CR70","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ijpharm.2016.06.137","volume":"514","author":"E Albarahmieh","year":"2016","unstructured":"Albarahmieh E, Qi S, Craig DQM. Hot melt extruded transdermal films based on amorphous solid dispersions in Eudragit RS PO: the inclusion of hydrophilic additives to develop moisture-activated release systems. Int J Pharm. 2016;514(1):270\u201381. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.06.137.","journal-title":"Int J Pharm"},{"issue":"1","key":"4200_CR71","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.apsb.2013.11.001","volume":"4","author":"Y Huang","year":"2014","unstructured":"Huang Y, Dai WG. Fundamental aspects of solid dispersion technology for poorly soluble drugs. Acta Pharm Sin B. 2014;4(1):18\u201325. https:\/\/doi.org\/10.1016\/j.apsb.2013.11.001.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"4200_CR72","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0939-6411(00)00076-X","volume":"50","author":"C Leuner","year":"2000","unstructured":"Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47\u201360. https:\/\/doi.org\/10.1016\/S0939-6411(00)00076-X.","journal-title":"Eur J Pharm Biopharm"},{"issue":"6","key":"4200_CR73","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ajps.2018.02.010","volume":"13","author":"C Zhang","year":"2018","unstructured":"Zhang C, Xu T, Zhang D, He W, Wang S, Jiang T. Disulfiram thermosensitive in-situ gel based on solid dispersion for cataract. Asian J Pharm Sci. 2018;13(6):527\u201335. https:\/\/doi.org\/10.1016\/j.ajps.2018.02.010.","journal-title":"Asian J Pharm Sci"},{"key":"4200_CR74","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jconrel.2018.04.014","volume":"279","author":"N Li","year":"2018","unstructured":"Li N, Taylor LS. Tailoring supersaturation from amorphous solid dispersions. J Control Release. 2018;279:114\u201325. https:\/\/doi.org\/10.1016\/j.jconrel.2018.04.014.","journal-title":"J Control Release"},{"key":"4200_CR75","unstructured":"ICH, Q8(R2) Pharmaceutical Development. International Council for Harmonisation. 2008. Available at: https:\/\/database.ich.org\/sites\/default\/files\/Q8_R2_Guideline.pdf. Accessed: 01 Jul 2026."},{"key":"4200_CR76","unstructured":"ICH, Q9(R1) Quality Risk Management. International Council for Harmonisation. 2022. Available at: https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q9%28R1%29_Guideline_Step4_2022_1219.pdf. Accessed: 01 Jul 2026."},{"key":"4200_CR77","unstructured":"ICH, Q10 Pharmaceutical Quality System. International Council for Harmonisation. 2008. Available at: https:\/\/database.ich.org\/sites\/default\/files\/Q10%20Guideline.pdf. Accessed: 01 Jul 2026."},{"key":"4200_CR78","unstructured":"ICH, Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. International Council for Harmonisation. 2019. Available at: https:\/\/database.ich.org\/sites\/default\/files\/Q12_Guideline_Step4_2019_1119.pdf. Accessed: 01 Jul 2026."},{"key":"4200_CR79","unstructured":"European Medicines Agency, Guideline on quality and equivalence of locally applied, locally acting cutaneous products. EMA\/CHMP\/QWP\/708282\/2018. 2024. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-quality-equivalence-locally-applied-locally-acting-cutaneous-products_en.pdf. Accessed: 01 Jul 2026."},{"key":"4200_CR80","unstructured":"U.S. Food and Drug Administration, Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs. Guidance for Industry. 2026. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/physicochemical-and-structural-q3-characterization-topical-drug-products-submitted-andas. Accessed: 01 Jul 2026."},{"key":"4200_CR81","unstructured":"European Medicines Agency, Guideline on the pharmaceutical quality of inhalation and nasal medicinal products - Revision 1. EMA\/CHMP\/QWP\/49313\/2005 Rev.1. 2025. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-pharmaceutical-quality-inhalation-nasal-medicinal-products-revision-1_en.pdf. Accessed: 01 Jul 2026."},{"key":"4200_CR82","unstructured":"European Medicines Agency, Guideline on sterilisation of the medicinal product, active substance, excipient and primary container. EMA\/CHMP\/CVMP\/QWP\/850374\/2015. 2019. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-sterilisation-medicinal-product-active-substance-excipient-and-primary-container_en.pdf. Accessed: 01 Jul 2026."},{"key":"4200_CR83","unstructured":"U.S. Food and Drug Administration, Sterile Drug Products Produced by Aseptic Processing \u2014 Current Good Manufacturing Practice. Guidance for Industry. FDA. 2004. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice. Accessed: 01 Jul 2026."},{"key":"4200_CR84","unstructured":"U.S. Food and Drug Administration, Pyrogen and Endotoxins Testing: Questions and Answers. Guidance for Industry. FDA. 2026. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pyrogen-and-endotoxins-testing-questions-and-answers. Accessed: 01 Jul 2026."},{"key":"4200_CR85","unstructured":"United States Pharmacopeia, <788> Particulate Matter in Injections. USP-NF. Available at: https:\/\/www.uspnf.com\/sites\/default\/files\/usp_pdf\/EN\/USPNF\/revisionGeneralChapter788.pdf. Accessed: 01 Jul 2026."},{"key":"4200_CR86","unstructured":"Wolff HM, Arth C, Quere L, M\u00fcller W, Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine. US10130589B2. UCB Pharma GmbH; LTS Lohmann Therapie Systeme AG. Published 2018 Nov 20."},{"key":"4200_CR87","unstructured":"Petersson K, Engell KM, Jansson J, Nielsen KT, Eriksson AH, Moore A, Vucen S, O\u2019Sullivan C, Crean A, Microneedle patch for delivering an active ingredient to skin. WO2016155891A1. LEO Pharma A\/S. Published 2016 Oct 6."},{"key":"4200_CR88","unstructured":"Wang Q, Liu H, Chen M, Wei Y, Zhao W, Dong Z, Microneedle transdermal drug delivery patch for treating rheumatoid arthritis and preparation method thereof. CN109528695B. Bengbu Medical College. Published 2022 Apr 19."},{"key":"4200_CR89","unstructured":"Shi J, Guo S, Xu X, Lai J, Lin Y, Mai Y, Self-dissolving microneedle for treating scar. CN111035628A. Guangdong Pharmaceutical University. Published 2020 Apr 21."},{"key":"4200_CR90","unstructured":"Bley RS, Conston SR, Yamamoto RK, Nguyen TT, Lunsford JP, Martinez DD, Phan LX, Ophthalmic drug compositions. WO2019053466A1. Oxular Ltd. Published 2019 Mar 21."},{"key":"4200_CR91","unstructured":"Ghebre-Sellassie I, Reisch R Jr, Parikh R, Fawzi MB, Nesbitt RU, A process for the preparation of a solid dispersion. EP0617612B1. Warner-Lambert Co LLC. Published 1997 Sep 10."},{"issue":"8","key":"4200_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/ph18081089","volume":"18","author":"J Quodbach","year":"2025","unstructured":"Quodbach J, Preis E, Karkossa F, Winck J, Finke JH, Steiner D. Novel strategies for the formulation of poorly water-soluble drug substances by different physical modification strategies with a focus on peroral applications. Pharmaceuticals (Basel). 2025;18(8):1089. https:\/\/doi.org\/10.3390\/ph18081089.","journal-title":"Pharmaceuticals (Basel)"},{"key":"4200_CR93","doi-asserted-by":"publisher","unstructured":"Jermain SV, Brough C, Williams RO III. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery - an update. Int J Pharm. 2018;535(1\u20132):379\u201392. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.10.051.","DOI":"10.1016\/j.ijpharm.2017.10.051"},{"issue":"7","key":"4200_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/polym17070833","volume":"17","author":"L Eltaib","year":"2025","unstructured":"Eltaib L. Polymeric nanoparticles in targeted drug delivery: unveiling the impact of polymer characterization and fabrication. Polymers (Basel). 2025;17(7):833. https:\/\/doi.org\/10.3390\/polym17070833.","journal-title":"Polymers (Basel)"},{"key":"4200_CR95","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2147\/IJN.S505427","volume":"20","author":"B Zheng","year":"2025","unstructured":"Zheng B, Liu D, Qin X, Zhang D, Zhang P. Mucoadhesive-to-mucopenetrating nanoparticles for mucosal drug delivery: a mini review. Int J Nanomedicine. 2025;20:2241\u201352. https:\/\/doi.org\/10.2147\/IJN.S505427.","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"4200_CR96","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101\u201324. https:\/\/doi.org\/10.1038\/s41573-020-0090-8.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"4200_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10143","volume":"4","author":"AC Anselmo","year":"2019","unstructured":"Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. Bioeng Transl Med. 2019;4(3):e10143. https:\/\/doi.org\/10.1002\/btm2.10143.","journal-title":"Bioeng Transl Med"},{"issue":"12","key":"4200_CR98","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1007\/s13346-024-01559-0","volume":"14","author":"B Rossier","year":"2024","unstructured":"Rossier B, Jordan O, All\u00e9mann E, Rodr\u00edguez-Nogales C. Nanocrystals and nanosuspensions: an exploration from classic formulations to advanced drug delivery systems. Drug Deliv Transl Res. 2024;14(12):3438\u201351. https:\/\/doi.org\/10.1007\/s13346-024-01559-0.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"4200_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jpp\/rgad097","volume":"76","author":"A Chettri","year":"2024","unstructured":"Chettri A, Subba A, Singh GP, Bag PP. Pharmaceutical co-crystals: A green way to enhance drug stability and solubility for improved therapeutic efficacy. J Pharm Pharmacol. 2024;76(1):1\u201312. https:\/\/doi.org\/10.1093\/jpp\/rgad097.","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"4200_CR100","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/pharmaceutics17030288","volume":"17","author":"OE Nicolaescu","year":"2025","unstructured":"Nicolaescu OE, R\u0103dulescu DM, Dr\u0103g\u0103nescu D, Andri\u021boiu CV, Tuchilu\u0219 C, Profire L. Cyclodextrins: Enhancing Drug Delivery, Solubility and Bioavailability for Modern Therapeutics. Pharmaceutics. 2025;17(3):288. https:\/\/doi.org\/10.3390\/pharmaceutics17030288.","journal-title":"Pharmaceutics"},{"key":"4200_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2024.102147","volume":"55","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Oz Y, Gu Y, Ahamad N, Shariati K, Chevalier J, et al. Rational design of polymeric micelles for targeted therapeutic delivery. Nano Today. 2024;55:102147. https:\/\/doi.org\/10.1016\/j.nantod.2024.102147.","journal-title":"Nano Today"},{"key":"4200_CR102","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.addr.2020.09.009","volume":"156","author":"D Hwang","year":"2020","unstructured":"Hwang D, Ramsey JD, Kabanov AV. Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. Adv Drug Deliv Rev. 2020;156:80\u2013118. https:\/\/doi.org\/10.1016\/j.addr.2020.09.009.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"4200_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16111376","volume":"16","author":"M Rehman","year":"2024","unstructured":"Rehman M, Tahir N, Sohail MF, Qadri MU, Duarte SOD, Brand\u00e3o P, et al. Lipid-based nanoformulations for drug delivery: an ongoing perspective. Pharmaceutics. 2024;16(11):1376. https:\/\/doi.org\/10.3390\/pharmaceutics16111376.","journal-title":"Pharmaceutics"},{"issue":"7","key":"4200_CR104","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1007\/s13346-021-01071-9","volume":"12","author":"D Mori","year":"2022","unstructured":"Mori D, Vaghela P, Patel K, Sojitra K, Patel M, Patel S, et al. Lipid-based emulsion drug delivery systems \u2014 a comprehensive review. Drug Deliv Transl Res. 2022;12(7):1616\u201339. https:\/\/doi.org\/10.1007\/s13346-021-01071-9.","journal-title":"Drug Deliv Transl Res"},{"key":"4200_CR105","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/s44174-022-00041-0","volume":"1","author":"R Kesharwani","year":"2023","unstructured":"Kesharwani R, Jaiswal P, Patel DK, Yadav PK. Lipid-Based Drug Delivery System (LBDDS): An Emerging Paradigm to Enhance Oral Bioavailability of Poorly Soluble Drugs. Biomed Mater Devices. 2023;1:648\u201363. https:\/\/doi.org\/10.1007\/s44174-022-00041-0.","journal-title":"Biomed Mater Devices"},{"issue":"9","key":"4200_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092055","volume":"10","author":"DV Bhalani","year":"2022","unstructured":"Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics. Biomedicines. 2022;10(9):2055. https:\/\/doi.org\/10.3390\/biomedicines10092055.","journal-title":"Biomedicines"},{"issue":"11","key":"4200_CR107","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1016\/j.apsb.2024.08.027","volume":"14","author":"B Xie","year":"2024","unstructured":"Xie B, Liu Y, Li X, Yang P, He W. Solubilization techniques used for poorly water-soluble drugs. Acta Pharm Sin B. 2024;14(11):4683\u2013716. https:\/\/doi.org\/10.1016\/j.apsb.2024.08.027.","journal-title":"Acta Pharm Sin B"},{"issue":"11","key":"4200_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14112366","volume":"14","author":"M He","year":"2022","unstructured":"He M, Zheng W, Wang N, Gao H, Ouyang D, Huang Z. Molecular dynamics simulation of drug solubilization behavior in surfactant and cosolvent injections. Pharmaceutics. 2022;14(11):2366. https:\/\/doi.org\/10.3390\/pharmaceutics14112366.","journal-title":"Pharmaceutics"},{"issue":"9","key":"4200_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11092440","volume":"11","author":"D Elsegaie","year":"2023","unstructured":"Elsegaie D, El-Nabarawi MA, Mahmoud HA, Teaima M, Louis D. A comparative study on cyclodextrin derivatives in improving oral bioavailability of etoricoxib as a model drug: formulation and evaluation of solid dispersion-based fast-dissolving tablets. Biomedicines. 2023;11(9):2440. https:\/\/doi.org\/10.3390\/biomedicines11092440.","journal-title":"Biomedicines"},{"issue":"8","key":"4200_CR110","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.xphs.2024.04.031","volume":"113","author":"MM Smith-Craven","year":"2024","unstructured":"Smith-Craven MM, Dening TJ, Basra AK, Hageman MJ. Enhanced Dissolution of Amphotericin B through Development of Amorphous Solid Dispersions Containing Polymer and Surfactants. J Pharm Sci. 2024;113(8):2454\u201363. https:\/\/doi.org\/10.1016\/j.xphs.2024.04.031.","journal-title":"J Pharm Sci"},{"key":"4200_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103602","volume":"74","author":"AM Pironi","year":"2022","unstructured":"Pironi AM, Melero A, Eloy JO, Guillot AJ, Pini Santos K, Chorilli M. Solid dispersions included in poloxamer hydrogels have favorable rheological properties for topical application and enhance the in vivo antiinflammatory effect of ursolic acid. J Drug Deliv Sci Technol. 2022;74:103602. https:\/\/doi.org\/10.1016\/j.jddst.2022.103602.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"17","key":"4200_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/nano13172419","volume":"13","author":"M Rahman","year":"2023","unstructured":"Rahman M, Radgman K, Tarabokija J, Ahmad S, Bilgili E. Preparation and characterization of spray-dried hybrid nanocrystal\u2013amorphous solid dispersions (HyNASDs) for supersaturation enhancement of a slowly crystallizing drug. Nanomaterials. 2023;13(17):2419. https:\/\/doi.org\/10.3390\/nano13172419.","journal-title":"Nanomaterials"},{"issue":"7","key":"4200_CR113","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-023-02666-w","volume":"24","author":"P Mandati","year":"2023","unstructured":"Mandati P, Nyavanandi D, Narala S, Alzahrani A, Vemula SK, Repka MA. A comparative assessment of cocrystal and amorphous solid dispersion printlets developed by hot melt extrusion paired fused deposition modeling for dissolution enhancement and stability of ibuprofen. AAPS PharmSciTech. 2023;24(7):203. https:\/\/doi.org\/10.1208\/s12249-023-02666-w.","journal-title":"AAPS PharmSciTech"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04200-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04200-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04200-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:54:21Z","timestamp":1791302061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04200-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":113,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4200"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04200-6","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"18 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}